1
|
Koziol-White CJ, Ghosh A, Sandner P, Erzurum SE, Stuehr DJ, Panettieri RA. Soluble Guanylate Cyclase Agonists Induce Bronchodilation in Human Small Airways. Am J Respir Cell Mol Biol 2020; 62:43-48. [PMID: 31340135 PMCID: PMC6938135 DOI: 10.1165/rcmb.2019-0001oc] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2019] [Accepted: 07/24/2019] [Indexed: 01/11/2023] Open
Abstract
The soluble guanylyl cyclase (sGC)-cyclic guanosine monophosphate signaling pathway evokes vascular smooth muscle relaxation; whether this pathway mediates airway smooth muscle relaxation remains controversial. We posit that sGC activators are equi-effective as β-agonists in reversing contractile agonist-induced airway smooth muscle shortening. To provide clarity, we tested the efficacy of sGC stimulator and activator drugs, BAY 41-2272 and BAY 60-2270, respectively, in reversing bronchoconstriction of human small airways using human precision-cut lung slices (hPCLS). Both BAY drugs reversed carbachol-induced bronchoconstriction to a maximal degree comparable to that of formoterol. Moreover, the sGC drugs remained effective bronchodilators despite formoterol-induced desensitization of the airways. Analysis of the hPCLS after their activation by sGC or β2-adrenergic receptor agonist showed distinct cyclic nucleotide accumulation in the hPCLS. Collectively, these data suggest that cAMP and cyclic guanosine monophosphate pathways are equi-effective for reversing carbachol-induced bronchoconstriction in the human airway via separate and distinct second messenger pathways. This should open the door for future studies to test whether sGC-targeted drugs alone or in combination can serve as effective bronchodilators in asthma and chronic obstructive pulmonary disease.
Collapse
Affiliation(s)
- Cynthia J. Koziol-White
- Rutgers Institute for Translational Medicine and Science, Rutgers University, New Brunswick, New Jersey
| | - Arnab Ghosh
- Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio; and
| | - Peter Sandner
- Bayer AG, Pharmaceuticals R&D, Pharma Research Center, Wuppertal, Germany
| | - Serpil E. Erzurum
- Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio; and
| | - Dennis J. Stuehr
- Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio; and
| | - Reynold A. Panettieri
- Rutgers Institute for Translational Medicine and Science, Rutgers University, New Brunswick, New Jersey
| |
Collapse
|
2
|
Mastromatteo-Alberga P, Placeres-Uray F, Alfonzo-González MA, Alfonzo RGD, Becemberg ILD, Alfonzo MJ. A novel PDE1A coupled to M2AChR at plasma membranes from bovine tracheal smooth muscle. J Recept Signal Transduct Res 2015; 36:278-87. [PMID: 26513204 DOI: 10.3109/10799893.2015.1101136] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Muscarinic antagonists, via muscarinic receptors increase the cAMP/cGMP levels at bovine tracheal smooth muscle (BTSM) through the inhibition of phosphodiesterases (PDEs), displaying a similar behavior of vinpocetine (a specific-PDE1 inhibitor). The presence of PDE1 hydrolyzing both cyclic nucleotides in BTSM strips was revealed. Moreover, a vinpocetine and muscarinic antagonists inhibited PDE1 located at plasma membranes (PM) fractions from BTSM showing such inhibition, an M(2)AChR pharmacological profile. Therefore, a novel Ca(2+)/CaM dependent and vinpocetine inhibited PDE1 was purified and characterized at PM fractions from BTSM. This PDE1 activity was removed from PM fractions using a hypotonic buffer and purified some 38 fold using two columns (Q-Sepharose and CaM-agarose). This PDE1 was stimulated by CaM and inhibited by vinpocetine showing two bands in PAGE-SDS (56, 58 kDa) being the 58 kDa identified as PDE1A by Western blotts. This PDE1A activity was assayed with [(3)H]cGMP and [(3)H]cAMP exhibiting a higher affinity as Km (μM) for cGMP than cAMP but being close values with V(max) cAMP/cGMP ratio of 1.5. The co-factor Mg(2+) showed similar K(A) (mM) for both cyclic nucleotides. Vinpocetine showed similar inhibition concentration 50% (IC(50) of 4.9 and 4.6 μM) for cAMP and cGMP, respectively. CaM stimulated the cyclic nucleotides hydrolysis by PDE1A exhibiting similar activation constant as K(CaM), in nM range. The original finding was the identification and purification of a vinpocetine and muscarinic antagonist-inhibited and CaM-activated PM-bound PDE1A, linked to M(2)AChR. A model of this novel signal transducing cascade for the regulation of cyclic nucleotides levels at BTSM is proposed.
Collapse
Affiliation(s)
- Patrizzia Mastromatteo-Alberga
- a Sección de Biomembranas, Facultad de Medicina, Universidad Central de Venezuela, Instituto de Medicina Experimental , Caracas , Venezuela
| | - Fabiola Placeres-Uray
- a Sección de Biomembranas, Facultad de Medicina, Universidad Central de Venezuela, Instituto de Medicina Experimental , Caracas , Venezuela
| | - Marcelo A Alfonzo-González
- a Sección de Biomembranas, Facultad de Medicina, Universidad Central de Venezuela, Instituto de Medicina Experimental , Caracas , Venezuela
| | - Ramona Gonzalez de Alfonzo
- a Sección de Biomembranas, Facultad de Medicina, Universidad Central de Venezuela, Instituto de Medicina Experimental , Caracas , Venezuela
| | - Itala Lippo de Becemberg
- a Sección de Biomembranas, Facultad de Medicina, Universidad Central de Venezuela, Instituto de Medicina Experimental , Caracas , Venezuela
| | - Marcelo J Alfonzo
- a Sección de Biomembranas, Facultad de Medicina, Universidad Central de Venezuela, Instituto de Medicina Experimental , Caracas , Venezuela
| |
Collapse
|
3
|
Alfonzo MJ, Alfonzo RGD, Alfonzo González M, de Becemberg IL. Muscarinic drugs regulate the PKG-II-dependent phosphorylation of M3 muscarinic acetylcholine receptors at plasma membranes from airway smooth muscle. J Recept Signal Transduct Res 2015; 35:319-28. [PMID: 26053513 DOI: 10.3109/10799893.2014.982826] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Muscarinic agonists induce the activation of the airway smooth muscle (ASM) leading to smooth muscle contraction, important in asthma. This activation is mediated through M2/M3 muscarinic acetylcholine receptors (mAChRs). Muscarinic receptor activity, expressed as [(3)H]QNB binding at plasma membranes from bovine tracheal smooth muscle (BTSM), increased with cGMP and was augmented significantly cGMP plus ATP but diminished with the PKG-II inhibitor, Sp-8-pCPT-cGMPS. The [(3)H]-QNB binding was accelerated by okadaic acid, (OKA), a protein phosphatase (PPase) inhibitor. These two results indicated the involvement of a membrane-bound PPase. Moreover, a cGMP-dependent-[(32)P]γATP phosphorylation of plasma membranes from BTSM was stimulated at low concentrations of muscarinic agonist carbamylcholine (CC). However, higher amounts of CC produced a significant decrement of [(32)P]-labeling. A selective M3mAChR antagonist, 4-DAMP produced a dramatic inhibition of the basal and CC-dependent [(32)P]-labeling. The [(32)P] labeled membrane sediments were detergent solubilized and immunoprecipitated with specific M2/M3mAChR antibodies. The M3mAChR immuno-precipitates exhibited the highest cGMP-dependent [(32)P]-labeling, indicating it is a PKG-II substrate. Experiments using synthetic peptides from the C-terminal of the third intracellular loop (i3) of both M2mAChR (356-369) and M3mAChR (480-493) as external PKG-II substrates resulted in the i3M3-peptide being heavily phosphorylated. These results indicated that PKG-II phosphorylated the M3mAChR at the i3M3 domain ((480)MSLIKEKK(485)), suggesting that Ser(481) may be the target. Finally, this phosphorylation site seems to be regulated by a membrane-bound PPase linked to muscarinic receptor. These findings are important to understand the role of M3mAChR in the patho-physiology of ASM involved in asthma and COPD.
Collapse
Affiliation(s)
- Marcelo J Alfonzo
- a Facultad de Medicina, Sección de Biomembranas , Instituto de Medicina Experimental (IME), Universidad Central de Venezuela , Sabana Grande, Caracas , Venezuela
| | - Ramona González de Alfonzo
- a Facultad de Medicina, Sección de Biomembranas , Instituto de Medicina Experimental (IME), Universidad Central de Venezuela , Sabana Grande, Caracas , Venezuela
| | - Marcelo Alfonzo González
- a Facultad de Medicina, Sección de Biomembranas , Instituto de Medicina Experimental (IME), Universidad Central de Venezuela , Sabana Grande, Caracas , Venezuela
| | - Itala Lippo de Becemberg
- a Facultad de Medicina, Sección de Biomembranas , Instituto de Medicina Experimental (IME), Universidad Central de Venezuela , Sabana Grande, Caracas , Venezuela
| |
Collapse
|
4
|
Placeres-Uray FA, Febres-Aldana CA, Fernandez-Ruiz R, Gonzalez de Alfonzo R, Lippo de Becemberg IA, Alfonzo MJ. M2 Muscarinic acetylcholine receptor modulates rat airway smooth muscle cell proliferation. World Allergy Organ J 2013; 6:22. [PMID: 24377382 PMCID: PMC3898804 DOI: 10.1186/1939-4551-6-22] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2013] [Accepted: 12/17/2013] [Indexed: 01/13/2023] Open
Abstract
Airways chronic inflammatory conditions in asthma and COPD are characterized by tissue remodeling, being smooth muscle hyperplasia, the most important feature. Non-neuronal and neuronal Acetylcholine acting on muscarinic receptors (MAChRs) has been postulated as determinant of tissue remodeling in asthma and COPD by promoting proliferation and phenotypic changes of airway smooth muscle cells (ASMC). The objective was to evaluate proliferative responses to muscarinic agonist as carbamylcholine (Cch) and to identify the MAchR subtype involved. ASMC were isolated from tracheal fragments of Sprague-Dawley rats by enzymatic digestion. Proliferation assays were performed by MTS-PMS method. Viability was confirmed by trypan blue exclusion method. Mitogens as, epidermal growth factor (EGF), Tumor necrosis factor-alpha (TNF-α) and fetal bovine serum (FBS) increased ASMC proliferation (p < 0.05, n = 5). Cch alone increased ASMC proliferation at 24 and 48 hrs. However, combination of Cch with other mitogens exhibited a dual effect, synergistic proliferation effect in the presence of EGF (5 ng/mL) and 5% FBS and inhibiting the proliferation induced by 10% FBS, EGF (10 ng/mL) and TNF-α (10 ng/mL). To determine the MAChR subtype involved in these biological responses, a titration curve of selective muscarinic antagonists were performed. The Cch stimulatory and inhibitory effects on ASCM proliferation was blocked by AF-DX-116 (M2AChR selective antagonist), in greater proportion than 4-DAMP (M3AChR selective antagonist), suggesting that the modulation of muscarinic agonist-induced proliferation is M2AChR mediated responses. Thus, M2AChR can activate multiple signal transduction systems and mediate both effects on ASMC proliferation depending on the plethora and variable airway microenvironments existing in asthma and COPD.
Collapse
Affiliation(s)
- Fabiola A Placeres-Uray
- Sección de Biomembranas, Instituto de Medicina Experimental, Facultad de Medicina, Universidad Central de Venezuela (U.C.V), Caracas, Venezuela
| | - Christopher A Febres-Aldana
- Sección de Biomembranas, Instituto de Medicina Experimental, Facultad de Medicina, Universidad Central de Venezuela (U.C.V), Caracas, Venezuela
| | - Ruth Fernandez-Ruiz
- Sección de Biomembranas, Instituto de Medicina Experimental, Facultad de Medicina, Universidad Central de Venezuela (U.C.V), Caracas, Venezuela
| | - Ramona Gonzalez de Alfonzo
- Sección de Biomembranas, Instituto de Medicina Experimental, Facultad de Medicina, Universidad Central de Venezuela (U.C.V), Caracas, Venezuela
| | - Itala A Lippo de Becemberg
- Sección de Biomembranas, Instituto de Medicina Experimental, Facultad de Medicina, Universidad Central de Venezuela (U.C.V), Caracas, Venezuela
| | - Marcelo J Alfonzo
- Sección de Biomembranas, Instituto de Medicina Experimental, Facultad de Medicina, Universidad Central de Venezuela (U.C.V), Caracas, Venezuela
| |
Collapse
|
5
|
Alfonzo MJ, De Alfonzo RG, Alfonzo-González MA, De Becemberg IL. Cyclic GMP regulates M₃AChR activity at plasma membranes from airway smooth muscle. Mol Membr Biol 2013; 30:403-17. [PMID: 24175711 DOI: 10.3109/09687688.2013.851419] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Muscarinic acetylcholine receptors MAChRs from Bovine Tracheal Smooth Muscle (BTSM) plasma membranes are responsible for the cGMP rise and signal-amplitude peaks associated with smooth muscle contraction present in bronchial asthma. These MAChRs bind [(3)H]QNB and exhibit the classic G Protein Coupled-Receptor (GPCR) behavior towards muscarinic agonist and antagonists that is sensitive to sensitive to GTP analogs. Interestingly, the [(3)H]QNB binding activity was stimulated by cGMP and ATP, and was enhanced by IBMX and Zaprinast, inhibitors of cGMP-PDE. Cyclic GMP plus ATP affected the agonist-antagonist muscarinic binding activities. Thus, the high affinity agonist (Carbamylcholine) binding sites disappeared, whereas, 4-DAMP, a M3 selective antagonist displayed an additional high affinity-binding site. In contrast, non-selective (atropine) and M2-selective (methoctramine and gallamine) antagonists revealed one low binding site. Moreover, the 4-DAMP-mustard alkylation of the MAChRs blocked the cGMP effect indicating that the M3AChR is the main receptor target of cGMP. Interestingly, these cGMP effects were potentiated by an activator (Sp-8-pCPT-cGMPS), and diminished by an inhibitor (Rp-8-pCPT-CGMPS), of cGMP-dependent protein kinase (PKG-II), which was detected by Western blotting using specific PKG II antibodies. Finally, plasma membrane M3AChRs were phosphorylated in a cGMP-dependent manner and this novel post-translational reversible modification at M3AChRs may act as a feedback mechanism to terminate the cGMP dependent muscarinic signal transduction cascades at the sarcolema of BTSM.
Collapse
Affiliation(s)
- Marcelo J Alfonzo
- Sección de Biomembranas, Instituto de Medicina Experimental (IME), Facultad de Medicina, Universidad Central de Venezuela (UCV) , Caracas , Venezuela
| | | | | | | |
Collapse
|
6
|
Soluble guanylyl cyclase is reduced in airway smooth muscle cells from a murine model of allergic asthma. World Allergy Organ J 2013; 3:271-6. [PMID: 23282985 PMCID: PMC3651105 DOI: 10.1097/wox.0b013e318201d80b] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
Airway remodeling plays an important role in the development of airway
hyperresponsiveness in asthma. Muscarinic agonists such as carbamylcholine
increased cyclic GMP (cGMP) levels in bovine tracheal smooth muscle strips, via
stimulation of NO-sensitive soluble guanylylcyclase (NO-sGC), which is an enzyme
highly expressed in the lungs. cGMP production, by activation of a NO-sGC, may
contribute to airway smooth muscle relaxation. To determine whether the
bronchoconstriction observed in asthma is accompanied by changes in this NO-sGC
activity, we used a well-established murine model, ovalbumin-airway smooth
muscle cells (OVA-ASMCs) of allergic asthma to evaluate such hypothesis.
Histologic studies of trachea specimens showed the existence of inflammation,
hyperplasia and tissue remodeling in OVA-ASMCs. Interestingly, cultured
OVA-ASMCs showed lower GC basal activity than CONTROL-ASMCs. Also, we found that
both OVA-ASMCs and CONTROL cells exposed to carbamylcholine and sodium
nitroprusside and combinations of both drugs increased cGMP levels, which were
inhibited by 1H-[1,2,4]oxadiazolo[4,3-] quinoxalin-1-one. All the experimental
evidence suggests that NO-sGC activity is reduced in isolated ASMCss from
experimental asthma murine model.
Collapse
|
7
|
Tsai EJ, Liu Y, Koitabashi N, Bedja D, Danner T, Jasmin JF, Lisanti MP, Friebe A, Takimoto E, Kass DA. Pressure-overload-induced subcellular relocalization/oxidation of soluble guanylyl cyclase in the heart modulates enzyme stimulation. Circ Res 2012; 110:295-303. [PMID: 22095726 PMCID: PMC4264382 DOI: 10.1161/circresaha.111.259242] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/20/2011] [Accepted: 11/08/2011] [Indexed: 01/17/2023]
Abstract
RATIONALE Soluble guanylyl cyclase (sGC) generates cyclic guanosine monophophate (cGMP) upon activation by nitric oxide (NO). Cardiac NO-sGC-cGMP signaling blunts cardiac stress responses, including pressure-overload-induced hypertrophy. The latter itself depresses signaling through this pathway by reducing NO generation and enhancing cGMP hydrolysis. OBJECTIVE We tested the hypothesis that the sGC response to NO also declines with pressure-overload stress and assessed the role of heme-oxidation and altered intracellular compartmentation of sGC as potential mechanisms. METHODS AND RESULTS C57BL/6 mice subjected to transverse aortic constriction (TAC) developed cardiac hypertrophy and dysfunction. NO-stimulated sGC activity was markedly depressed, whereas NO- and heme-independent sGC activation by BAY 60-2770 was preserved. Total sGCα(1) and β(1) expression were unchanged by TAC; however, sGCβ(1) subunits shifted out of caveolin-enriched microdomains. NO-stimulated sGC activity was 2- to 3-fold greater in Cav3-containing lipid raft versus nonlipid raft domains in control and 6-fold greater after TAC. In contrast, BAY 60-2770 responses were >10 fold higher in non-Cav3 domains with and without TAC, declining about 60% after TAC within each compartment. Mice genetically lacking Cav3 had reduced NO- and BAY-stimulated sGC activity in microdomains containing Cav3 for controls but no change within non-Cav3-enriched domains. CONCLUSIONS Pressure overload depresses NO/heme-dependent sGC activation in the heart, consistent with enhanced oxidation. The data reveal a novel additional mechanism for reduced NO-coupled sGC activity related to dynamic shifts in membrane microdomain localization, with Cav3-microdomains protecting sGC from heme-oxidation and facilitating NO responsiveness. Translocation of sGC out of this domain favors sGC oxidation and contributes to depressed NO-stimulated sGC activity.
Collapse
Affiliation(s)
- Emily J. Tsai
- Section in Cardiology, Department of Medicine, Temple University School of Medicine, Philadelphia, PA
- Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA
- Division of Cardiology, Department of Medicine, Johns Hopkins University Medical Institutions, Baltimore, MD
| | - Yuchuan Liu
- Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA
| | - Norimichi Koitabashi
- Division of Cardiology, Department of Medicine, Johns Hopkins University Medical Institutions, Baltimore, MD
| | - Djahida Bedja
- Department of Comparative Medicine and Comparative Pathology, Johns Hopkins University Medical Institutions, Baltimore, MD 21205
| | - Thomas Danner
- Division of Cardiology, Department of Medicine, Johns Hopkins University Medical Institutions, Baltimore, MD
| | - Jean-Francois Jasmin
- Department of Stem Cell Biology & Regenerative Medicine, Thomas Jefferson University, Philadelphia, PA
| | - Michael P. Lisanti
- Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA
| | - Andreas Friebe
- Physiologisches Institut I, Universität Würzburg, Würzburg, Germany
| | - Eiki Takimoto
- Division of Cardiology, Department of Medicine, Johns Hopkins University Medical Institutions, Baltimore, MD
| | - David A. Kass
- Division of Cardiology, Department of Medicine, Johns Hopkins University Medical Institutions, Baltimore, MD
| |
Collapse
|